Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Marissa Locastro, BS, Kah Poh Loh, MBBCHBAO, Andrea M. Baran, MS, Jane L. Liesveld, MD, Michael W. Becker, MD, Kristen Marie O'Dwyer, MD, Eric Huselton, MD, Omar S. Aljitawi, MD, Megan Baumgart, MD, Eric Snyder, Benzi Kluger, MD, Jason H. Mendler, MD PhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139475

Published: 2020

Journal Articles

Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells

Charles C. Chu, PhD, Jonathan J. Pinney, PhD, Sara K. Blick-Nitko, MS, Andrea M. Baran, MS, Derick R. Peterson, PhD, Hannah E. Whitehead, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Paul M. Barr, MD, Karl R. VanDerMeid, BS, Michael Rusty Elliott, PhD, Clive S. Zent, MD

Blood (2020) 136 (Supplement 1): 45.

https://doi.org/10.1182/blood-2020-139483

Published: 2020

Journal Articles

A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma

Patrick M. Reagan, MD, Craig A. Portell, MD, Carla Casulo, MD, Andrea M. Baran, MS, Allison Magnuson, DO, Paul M. Barr, MD, Yelena Lerman, PhD, Krista N French, Jonathan W. Friedberg, MD MSSc

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-140384

Published: 2020

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML)

Jodi J Lipof, MD, Dharmini Manogna, MD, Andrea M. Baran, MS, Bassil Said, MD, Michael W. Becker, MD, Jason H. Mendler, MD PhD, Omar S. Aljitawi, MD, Kristen Marie O'Dwyer, MD, Eric Huselton, MD, Richard Burack, MD PhD, Margaret Blaney, Taylor Douglas, Jane L. Liesveld, MD, Kah Poh Loh, MBBCHBAO

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-136739

Published: 2020

Journal Articles

A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Shuo Ma, MD PhD, Clive S. Zent, MD, Andrea M. Baran, MS, Andrew Bui, Philip J Meacham, PhD, Ashley Morrison, RN, Kelsey Holkovic, RN, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P. Miskin, MSc, Michael S. Weiss, Jonathan W. Friedberg, MD MSSc, Brian T. Hill, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134818

Published: 2020

Journal Articles

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Brian T. Hill, MD, Shuo Ma, MD PhD, Andrea M Baran, MS, Andrew Bui, Philip J Meacham, MS, Ashley Morrison, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S Weiss, Jonathan W. Friedberg, MD, Clive S Zent, MD

Blood (2019) 134 (Supplement_1): 360.

https://doi.org/10.1182/blood-2019-123404

Published: 2019

Journal Articles

Clinical and Quality of Life Predictors of Failure to Achieve Event Free Survival at 24 Months in Patients Aged 70 Years and Older with Diffuse Large B-Cell Lymphoma

Patrick M. Reagan, MD, Andrea M Baran, MS, Matthew J. Maurer, MS, Andrew L. Feldman, MD, Thomas M. Habermann, MD, Susan L. Slager, PhD, Gita Thanarajasingam, MD, Kathleen J Yost, PhD, Brian K. Link, MD, James R. Cerhan, MD PhD, Carrie A. Thompson, MD

Blood (2018) 132 (Supplement 1): 3579.

https://doi.org/10.1182/blood-2018-99-118356

Published: 2018

Journal Articles

High Risk of Infections in Chronic Lymphocytic Leukemia Patients Treated with B-Cell Receptor Inhibitors

Annalynn M Williams, MS, Andrea M Baran, MS, Philip J Meacham, MS, Megan Herr, BS, Hugo E. Valencia, MD, Catherine Newsom, Nealansh Gupta, Michelle Janelsins, PhD, Paul M. Barr, Clive S Zent, MD

Blood (2016) 128 (22): 3203.

https://doi.org/10.1182/blood.V128.22.3203.3203

Published: 2016

NARROW

Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS)

Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells

A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML)

A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Clinical and Quality of Life Predictors of Failure to Achieve Event Free Survival at 24 Months in Patients Aged 70 Years and Older with Diffuse Large B-Cell Lymphoma

High Risk of Infections in Chronic Lymphocytic Leukemia Patients Treated with B-Cell Receptor Inhibitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only